Constitutive JAK and/or STAT activation is found in most myeloproliferative neoplasms and in many other hematopoietic malignancies. It is frequently a biomarker of poor prognosis. The underlying molecular aberrations include activating mutations in or overexpression of signaling components (cytokine receptor, JAK, STAT), or rare JAK fusion proteins.

The research area investigates the oncogenic properties of aberrant levels of STATs 3, 5 and of mutants of TYK2 and STATs 3, 5 with respect to hematopoietic lineage-specific tumor initiation and disease progression.